<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00607295</url>
  </required_header>
  <id_info>
    <org_study_id>SNUH-OG-07-211</org_study_id>
    <nct_id>NCT00607295</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Clino-san on Vaginal Dryness of Breast Cancer Patients</brief_title>
  <official_title>Prospective Randomized Study on Efficacy and Safety of Clino-sanÂ® in the Management of Vaginal Dryness in Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Although after treatment for breast cancer such as chemotherapy or hormonal therapy,
           urogenital atrophy is common, the patients are seldomly treated for several reasons.
           Management of this problem is important for improving quality of life.

        2. &quot;Clino-san&quot; is a kind of vaginal lubricant with pH 5 which is similar pH of
           premenopausal vaginal discharge. After randomization of patients, they are treated with
           Clino-san or placebo 3 times/week for 12 weeks.

        3. We check the vaginal symptoms, vag dryness severity score, and ultrasonography at
           baseline, 4, 8, and 12 weeks of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>vaginal dryness score</measure>
    <time_frame>for 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>sexual dysfunction</measure>
    <time_frame>for 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">98</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Vaginal Atrophy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clino-san 2ml vaginal application 3 times per week for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo 2ml vaginal application 3 times per week for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clino-san vaginal lubricant</intervention_name>
    <description>Clino-san 2ml vaginal application 3 times per week for 12 weeks</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  breast cancer patients

          -  who are treated with chemotherapy or hormonal therapy

          -  who experience no menstruation after the previous therapy

          -  who complain of vaginal dryness

        Exclusion Criteria:

          -  other cancer patients

          -  other severe disease

          -  poor compliance
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae Weon Kim, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2008</study_first_submitted>
  <study_first_submitted_qc>February 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2008</study_first_posted>
  <last_update_submitted>July 23, 2010</last_update_submitted>
  <last_update_submitted_qc>July 23, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 27, 2010</last_update_posted>
  <responsible_party>
    <name_title>Yookyung Lee</name_title>
    <organization>Seoul National University Hospital</organization>
  </responsible_party>
  <keyword>chemotherapy</keyword>
  <keyword>hormonal therapy</keyword>
  <keyword>urogenital atrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>July 19, 2011</submitted>
    <returned>August 11, 2011</returned>
    <submitted>April 18, 2016</submitted>
    <returned>May 24, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

